Levodopa + Carbidopa + Entacapona Generis

Levodopa, Carbidopa, Entacapone, the active ingredients in Levodopa + Carbidopa + Entacapone Generis, are a dopamine precursor combined with a peripheral decarboxylase inhibitor and a catechol‑O‑methyltransferase inhibitor, presented as an oral tablet for systemic use. The combination is used to treat Parkinson's disease and to manage motor fluctuations in patients already receiving levodopa therapy.

GNH USA supplies Levodopa + Carbidopa + Entacapone Generis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa/Entacapone is indicated for the treatment of Parkinsonian disorders and related motor complications. - Parkinson's disease: Improves bradykinesia, rigidity, tremor and overall motor function. - Motor fluctuations in Parkinson's disease: Reduces "off" periods and extends "on" time when added to levodopa therapy. - Adjunct therapy for levodopa‑responsive Parkinsonism: Enhances central dopamine availability and stabilises symptom control.

Levodopa/Carbidopa/Entacapone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional episodes, especially at treatment initiation. - Orthostatic hypotension: dizziness upon standing. - Dyskinesia: involuntary movements, often dose‑related. - Hallucinations: visual disturbances, more common in older patients. - Insomnia: difficulty maintaining sleep.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity. - Severe depression or suicidal thoughts: requires immediate medical attention. - Pulmonary edema: rare fluid accumulation in lungs. - Severe arrhythmias: uncommon cardiac rhythm disturbances.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular status: monitor blood pressure for orthostatic changes. - Evaluate psychiatric history: watch for hallucinations or mood alterations. - Adjust dose in renal impairment: consider reduced dosing in severe dysfunction. - Review concomitant medications: avoid drugs that may exacerbate dyskinesia. - Monitor for dyskinesia development: titrate levodopa component as needed. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Levodopa/Carbidopa/Entacapone interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol): may diminish dopaminergic effect. - High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive blood‑pressure lowering effect. - Iron or calcium supplements: reduce levodopa absorption if taken simultaneously. - SSRIs or SNRIs: may increase risk of serotonin syndrome when combined with MAO‑B inhibitors.